Ramsfjell V, Bryder D, Björgvinsdóttir H, Kornfält S, Nilsson L, Borge O J, Jacobsen S E
Stem Cell Laboratory, Department of Molecular Medicine and Gene Therapy, Institute for Laboratory Medicine, University Hospital of Lund, Lund, Sweden.
Blood. 1999 Dec 15;94(12):4093-102.
Recently, primitive human bone marrow (BM) progenitors supporting hematopoiesis in extended (>60 days) long-term BM cultures were identified. Such extended long-term culture-initiating cells (ELTC-IC) are of the CD34(+)CD38(-) phenotype, are quiescent, and are difficult to recruit into proliferation, implicating ELTC-IC as the most primitive human progenitor cells detectable in vitro. However, it remains to be established whether ELTC-IC can proliferate and potentially expand in response to early acting cytokines. Here, CD34(+)CD38(-) BM ELTC-IC (12-week) were efficiently recruited into proliferation and expanded in vitro in response to early acting cytokines, but conditions for expansion of ELTC-IC activity were distinct from those of traditional (5-week) LTC-IC and murine long-term repopulating cells. Whereas c-kit ligand (KL), interleukin-3 (IL-3), and IL-6 promoted proliferation and maintenance or expansion of murine long-term reconstituting activity and human LTC-IC, they dramatically depleted ELTC-IC activity. In contrast, KL, flt3 ligand (FL), and megakaryocyte growth and development factor (MGDF) (and KL + FL + IL-3) expanded murine long-term reconstituting activity as well as human LTC-IC and ELTC-IC. Expansion of LTC-IC was most optimal after 7 days of culture, whereas optimal expansion of ELTC-IC activity required 12 days, most likely reflecting the delayed recruitment of quiescent CD34(+)CD38(-) progenitors. The need for high concentrations of KL, FL, and MGDF (250 ng/mL each) and serum-free conditions was more critical for expansion of ELTC-IC than of LTC-IC. The distinct requirements for expansion of ELTC-IC activity when compared with traditional LTC-IC suggest that the ELTC-IC could prove more reliable as a predictor for true human stem cell activity after in vitro stem cell manipulation.
最近,在延长(>60天)的长期骨髓培养中支持造血的原始人类骨髓(BM)祖细胞被鉴定出来。这种延长的长期培养起始细胞(ELTC-IC)具有CD34(+)CD38(-)表型,处于静止状态,难以被招募进入增殖状态,这表明ELTC-IC是体外可检测到的最原始的人类祖细胞。然而,ELTC-IC是否能响应早期作用的细胞因子进行增殖并潜在地扩增仍有待确定。在这里,CD34(+)CD38(-) BM ELTC-IC(12周)在早期作用的细胞因子作用下被有效地招募进入增殖状态并在体外扩增,但ELTC-IC活性的扩增条件与传统的(5周)LTC-IC和小鼠长期重建造血细胞的细胞不同。虽然c-kit配体(KL)、白细胞介素-3(IL-3)和IL-6促进了小鼠长期重建造血活性和人类LTC-IC的增殖、维持或扩增,但它们显著消耗了ELTC-IC活性。相反,KL、flt3配体(FL)和巨核细胞生长和发育因子(MGDF)(以及KL + FL + IL-3)扩增了小鼠长期重建造血活性以及人类LTC-IC和ELTC-IC。LTC-IC在培养7天后扩增最为理想,而ELTC-IC活性的最佳扩增需要12天,这很可能反映了静止的CD34(+)CD38(-)祖细胞的延迟招募。与LTC-IC相比,ELTC-IC活性扩增对高浓度的KL、FL和MGDF(各250 ng/mL)以及无血清条件的需求更为关键。与传统LTC-IC相比,ELTC-IC活性扩增的不同要求表明,在体外干细胞操作后,ELTC-IC作为真正人类干细胞活性的预测指标可能更可靠。